Quo Vadis Trastuzumab?: Navigating Cardiac Safety Risk Estimates With Complex Cancer Treatments. 

 -  2019 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>2213-1779 
<br/><br/><label>Standard No.: </label>10.1016/j.jchf.2018.10.020 [doi] S2213-1779(18)30831-X [pii] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Breast Neoplasms<br/>*Heart Failure<br/>Cardiotoxicity<br/>Chemotherapy, Adjuvant<br/>Heart<br/>Humans<br/>Trastuzumab
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Heart & Vascular Institutena
<br/><br/><label>Index Terms--Function: </label><br/>Comment<br/>Editorial